Skip to main content
. 2020 Oct 15;9(10):844. doi: 10.3390/pathogens9100844

Table 1.

Summary of recent data on successful application of phages and lysin in experimental and clinical sepsis. ip—intraperitoneal application; iv—intravenous application.

Animal Model/Human Disease Pathogen Route and Schedule of Phage Administration Reference
Galleria mellonella larvae
mouse
Acinetobacter baumannii single injection
single ip MOI of 100
[6]
mouse Acinetobacter baumannii single ip 109 [7]
mouse Acinetobacter baumannii single ip MOI of 0.1–10 [8]
mouse Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Citrobacter freundii, Moraxella catarrhalis single ip MOI of 0.001–2 [9]
mouse Pseudomonas aeruginosa single ip 109 [10]
Di George syndrome with septicemia Pseudomonas aeruginosa iv for 3 days 3 × 105 every 6 h [15]
Acute kidney failure with septicemia Pseudomonas aeruginosa iv for 10 days concentration not given [16]
Endocarditis with septicemia (13 patients) Staphylococcus aureus iv for 14 days [17]
Disseminated mycobacterial infection Mycobacterium abscessus iv for 32 weeks 109 every 12 h for 32 weeks [18]
Endocarditis with septicemia (119 patients) Staphylococcus aureus Anti-staph lysin iv 0.12–0.25 mg/kg for 14 days [27]
HHS Vulnerability Disclosure